Skip to main content

Table 1 Baseline characteristics

From: Early hemodynamic impact of SGLT2 inhibitors in overweight cardiometabolic heart failure: beyond fluid offloading to vascular adaptation– a preliminary report

General characteristics

Age (years)

75 [58–84]

Male sex

12 (60)

Weight (kg)

68 [46-99.20]

BMI (kg/m2)

< 25

≥25 to < 30

≥30

26.40 [20.40–37.70]

6 (30)

9 (45)

5 (25)

Smoker

9 (45)

Dyslipidemia

18 (90)

Diabetes

4 (20)

Hypertension

18 (90)

Prior Myocardial infarction

8 (40)

Prior PCI

10 (50)

Prior CABG

5 (25)

CIED

3 (15)

CKD

5 (25)

COPD

4 (20)

OSAS

1 (5)

Atrial Fibrillation

paroxysmal

persistent

permanent

9 (45)

5 (25)

0 (0)

4 (20)

HF type

HFpEF

HFmrEF

HFrEF

20 (100)

13 (65)

5 (25)

2 (10)

Drugs therapy

Beta-blocker

18 (90)

Calcium channel blockers

1 (5)

ACEi

11 (55)

ARB

3 (15)

ARNI

2 (10)

MRA

4 (20)

Loop Diuretic

12 (60)

Thiazide Diuretic

1 (5)

SGLT2i

Empaglifozin

Dapaglifozin

20 (100)

11 (55)

9 (45)

  1. Values are expressed as median [min-max] or n (%)
  2. BMI- Body mass index; HF-Heart failure; HFpEF-Heart failure with preserved ejection fraction; HFmrEF- Heart failure with mildly reduced ejection fraction; HFrEF- Heart failure with reduced ejection fraction; PCI- Percutaneous coronary intervention; CABG- Coronary artery bypass graft surgery; CIED- Cardiac implantable electronic device; CKD– Chronic kidney disease; COPD- Chronic obstructive pulmonary disease; OSAS- Obstructive sleep apnea syndrome; ACEi– ACE inhibitor; ARB– Angiotensin receptor blocker; ARNI– Angiotensin receptor neprilisin inhibitor; MRA– Mineralocorticoids receptor antagonists; SGLT2i- Sodium-glucose co-transporter 2 inhibitors